Company
Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine has 57 drugs tracked on RxWires: 3 post-market, 20 in Phase 3, 1 in Phase 2/3, 12 in Phase 2, 5 in Phase 1/2, 16 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Ivarmacitinib | Post-Market | Rheumatoid Arthritis |
| Bupivacaine Liposome Injection | Post-Market | Local Analgesia Via Infiltration |
| Henagliflozin 10 mg daily | Post-Market | Metabolic Dysfunction-associated Steatotic Liver Disease |
| Fluzoparib | Phase 3 | Metastatic Pancreatic Cancer |
| Famitinib | Phase 3 | Colorectal Cancer Metastatic |
| Camrelizumab 200mg | Phase 3 | PD-L1 Positive Non-small Cell Lung Cancer |
| Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor |
| Apatinib | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Herombopag tablets | Phase 3 | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery |
| SHR-1210 | Phase 3 | Gastric Cancer |
| SHR-3167 Injection | Phase 3 | Type 2 Diabetes |
| dexmedetomidine hydrochloride nasal spray | Phase 3 | Preoperative Sedation |
| FH-006 | Phase 3 | Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy |
| HRS-4642 + AG | Phase 3 | KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting |
| HRS-6209 + Letrozole | Phase 3 | Breast Cancer |
| Hetrombopag Olamine | Phase 3 | Patients With Chemotherapy-Induced Thrombocytopenia |
| HRS-8427 | Phase 3 | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) |
| Remimazolam Tosilate | Phase 3 | Sedation |
| HR091506 tablets + placebo of febuxostat tablets | Phase 3 | Gout With Hyperuricemia in Adults |
| Camrelizumab Plus Chemotherapy | Phase 3 | Triple Negative Breast Cancer |
| SHR8008 capsule | Phase 3 | Acute Vulvovaginal Candidiasis |
| SHR6390 | Phase 3 | Advanced Breast Cancer |
| HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Advanced Pancreatic Cancer |
| Hepatectomy Combined With Camrelizumab and Apatinib | Phase 2/3 | Hepatocellular Carcinoma |
| SHR-1701 | Phase 2 | Squamous Cell Carcinoma of Head and Neck |
| PD-1 inhibitor | Phase 2 | Head and Neck Cancer |
| Hetrombopag | Phase 2 | Breast Cancer |
| HRS-9190; under Inhalational Anesthesia | Phase 2 | Neuromuscular Blockade |
| Pyrotinib | Phase 2 | Breast Cancer Invasive |
| SHR4640 tablet | Phase 2 | Primary Gout and Hyperuricemia |
| SHR8554 Injection and SHR0410 Injection | Phase 2 | Pain |
| PEX168 or placebo | Phase 2 | Type 2 Diabetes |
| Combination therapy | Phase 2 | Advanced Esophageal Cancer |
| FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin | Phase 2 | Lung Cancer |
| flumatinib | Phase 2 | Myelogenous Leukemia, Chronic |
| Camrelizumab for Injection, Famitinib malate capsule, Paclitaxel For Injection(Albumin Bound) | Phase 2 | Advanced Solid Tumors |
| Bevacizumab； HRS-1167 | Phase 1/2 | Recurrent Ovarian Cancer |
| HRS-6213 | Phase 1/2 | Patients With Solid Tumors |
| HRS-7172 + AG + SHR-1316 | Phase 1/2 | Pancreatic Cancer |
| HRS-6209 in Combination with Fulvestrant | Phase 1/2 | Advanced Unresectable or Metastatic Breast Cancer |
| FH-006 for Injection | Phase 1/2 | Malignant Solid Tumor |
| SP2086 | Phase 1 | Type 2 Diabetes |
| SHR2285 tablet | Phase 1 | Thrombosis |
| Bupivacaine Liposome Injection T preparation | Phase 1 | Postoperative Local Analgesia |
| SHR1459 tablet | Phase 1 | B-cell Tumors |
| SHR-1501 | Phase 1 | Advanced Malignancies |
| SHR3162 | Phase 1 | Healthy Adult Male and Female Volunteers |
| SHR0532 | Phase 1 | Hypertension |
| INS068 injection | Phase 1 | Diabetes Mellitus |
| SHR7280 Tablets | Phase 1 | Endometriosis |
| HRS-7525 tablets | Phase 1 | Prostate Cancer |
| SHR2554 Tablets | Phase 1 | Malignant Tumor |
| PEX168 | Phase 1 | Type 2 Diabetes |
| SHR9146+SHR-1210 | Phase 1 | Tumor, Solid |
| SHR4394 | Phase 1 | Prostate Cancer |
| dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets | Phase 1 | High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) |
| SHR1459 fasted in P1, high-fat diet in P2 | Phase 1 | Healthy Adult Subjects |
Latest
Follow Jiangsu Hengrui Medicine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.